AbbVie Inc. reported results for the 2026 quarter with revenue of $16.99B and diluted EPS of $2.03, driven by strong growth in key brands and a rebound in net earnings versus the prior-year period.
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$16.99B$15.42B10.2% | Net income²$3.61B$938M285.2% | Diluted EPS³$2.03$0.52290.4% |
¹ Reported as “Net revenues”. ² Reported as “Net earnings attributable to AbbVie Inc.”. ³ Reported as “Diluted earnings per share attributable to AbbVie Inc.”.
Business Highlights
- Revenue growth: Worldwide net revenues rose about 11% year-to-date (10% on a constant-currency basis), led by Skyrizi, Rinvoq and strength in neuroscience products.
- Brand momentum: Strong uptake for Skyrizi, Rinvoq, Qulipta and Botox; Vyalev and Elahere posted double-digit to greater-than-100% growth.
- Humira decline: Humira sales fell roughly 36% amid biosimilar competition, partially offset by international expansion and new approvals.
- Pipeline and R&D: Approximately 90 programs with about 60 mid- or late-stage programs; multiple regulatory submissions, approvals and Phase 3 readouts expected over the next 12 months.
- Investments: Continued capital spending including a major U.S. manufacturing campus and new facilities, and a $650M upfront licensing payment to support launches.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.